News
2seventy and Bristol Myers Squibb currently share in U.S. commercialization of Abecma. Bristol Myers Squibb’s Opdualag paired with blockbuster immunotherapy Opdivo failed a clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback